Evelo Biosciences, Inc. Common Stock
EVLO
EVLO was delisted on the 11th of December, 2023.
64 hedge funds and large institutions have $332M invested in Evelo Biosciences, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 23 increasing their positions, 15 reducing their positions, and 10 closing their positions.
53% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 15
3% less funds holding
Funds holding: 66 → 64 (-2)
10% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 10
25% less call options, than puts
Call options by funds: $4.87M | Put options by funds: $6.53M
49% less capital invested
Capital invested by funds: $646M → $332M (-$314M)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$2.13M |
| 2 |
SOMRS
State of Michigan Retirement System
Lansing,
Michigan
|
+$1.98M |
| 3 |
Belvedere Trading
Chicago,
Illinois
|
+$1.36M |
| 4 |
Bessemer Group
Woodbridge,
New Jersey
|
+$607K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$481K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$662K |
| 2 |
AIMCA
Alberta Investment Management Corp (AIMCo)
Edmonton,
Alberta, Canada
|
-$550K |
| 3 |
D.E. Shaw & Co
New York
|
-$464K |
| 4 |
Amundi
Paris,
France
|
-$446K |
| 5 |
Millennium Management
New York
|
-$312K |
EVLO Hedge Fund Activity: Q3 2021 in Review
64 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Evelo Biosciences, Inc. Common Stock (EVLO) for Q3 2021, worth a combined $332M — down 49% from $646M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of EVLO and 9 opened new positions — a net loss of 1 holder — while 15 trimmed existing stakes and 23 added.
The largest buyer was Credit Suisse, adding an estimated $2.13M. The largest seller was Two Sigma Investments, cutting an estimated $662K.
- 64 institutional investors held Evelo Biosciences, Inc. Common Stock (EVLO) as of Q3 2021, down from 66 in Q2 2021.
- Funds reported $332M of Evelo Biosciences, Inc. Common Stock stock for Q3 2021, down 49% quarter-over-quarter.
- 9 funds opened new Evelo Biosciences, Inc. Common Stock positions in Q3 2021 and 10 closed out, a net change of -1 holder.
- The largest Evelo Biosciences, Inc. Common Stock buyer in Q3 2021 was Credit Suisse, an estimated $2.13M added.
- The largest Evelo Biosciences, Inc. Common Stock seller in Q3 2021 was Two Sigma Investments, an estimated $662K sold.
Based on aggregated 13F filings for Q3 2021.